AI Portfolio Summary
In 2025 Q4, Stonepine Capital Management, LLC maintained a portfolio of 89 distinct positions. The most significant new addition to the portfolio was CORBUS PHARMACEUTICA, which now represents 2.32% of the total fund value. They heavily accumulated shares in VERASTEM INC, increasing their position by 2.3%. The fund also reduced its exposure to BIOAGE LABS INC by 76.1%.
Total Positions
89
Quarter
2025 Q4
Top Holding
VSTM (15.4%)
Top 10 Concentration
53.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 89
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
VSTM
VERASTEM INC
|
Healthcare | 15.40% | 19.17% |
#1
Prev: #1
|
6.5 | 62,047 | 2.3% |
P
S
|
2,732,079 | $21,091,650 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ADMA
ADMA BIOLOGICS ...
|
Healthcare | 9.85% | 8.81% |
#2
Prev: #2
|
5.9 | 1,000 | 0.1% |
P
S
|
740,000 | $13,497,600 | 2017 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EOLS
EVOLUS INC
|
Healthcare | 7.92% | 7.67% |
#3
Prev: #3
|
6.2 | 95,197 | 6.2% |
P
S
|
1,631,588 | $10,850,060 | 2018 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ZVRA
ZEVRA THERAPEUT...
|
Healthcare | 3.72% | 6.26% |
#4
Prev: #4
|
2.0 | -240,912 | -29.7% |
P
S
|
569,088 | $5,099,028 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IKT
INHIBIKASE THER...
|
Healthcare | 3.51% | 0.97% |
#5
18
Prev: #23
|
4.9 | 1,613,128 | 219.5% |
P
S
|
2,348,147 | $4,813,701 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABEO
ABEONA THERAPEU...
|
Healthcare | 2.73% | 1.94% |
#6
9
Prev: #15
|
4.1 | 258,535 | 57.3% |
P
S
|
709,505 | $3,739,091 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NKTR
NEKTAR THERAPEU...
|
Healthcare | 2.62% | 3.93% |
#7
2
Prev: #5
|
2.0 | no change | no change |
P
S
|
85,000 | $3,593,800 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
INDV
INDIVIOR PLC
|
Healthcare | 2.62% | 1.96% |
#8
6
Prev: #14
|
2.0 | no change | no change |
P
S
|
100,000 | $3,588,000 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CRBP
CORBUS PHARMACE...
|
Healthcare | 2.32% | — |
#9
Prev: #—
|
4.4 | 389,916 | no change |
NEW
|
389,916 | $3,173,916 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KZIA
KAZIA THERAPEUT...
|
Healthcare | 2.32% | — |
#10
Prev: #—
|
4.4 | 460,359 | no change |
NEW
|
460,359 | $3,171,874 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XOMA
XOMA ROYALTY CO...
|
Healthcare | 2.23% | 3.62% |
#11
4
Prev: #7
|
1.4 | -459 | -0.4% |
P
S
|
115,000 | $3,057,850 | 2017 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VRCA
VERRICA PHARMAC...
|
Healthcare | 2.15% | — |
#12
Prev: #—
|
4.4 | 353,669 | no change |
NEW
|
353,669 | $2,938,989 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CYBN
CYBIN INC
|
Healthcare | 2.03% | — |
#13
Prev: #—
|
4.3 | 339,902 | no change |
NEW
|
339,902 | $2,780,398 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TELA
TELA BIO INC
|
Healthcare | 2.03% | 2.61% |
#14
1
Prev: #13
|
2.8 | 196,513 | 9.1% |
P
S
|
2,352,032 | $2,775,398 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ACAD
ACADIA PHARMACE...
|
Healthcare | 1.95% | 3.03% |
#15
7
Prev: #8
|
0.8 | -74,544 | -42.7% |
P
S
|
100,000 | $2,671,000 | 2018 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CRSP
CALL
CRISPR THERAPEU...
|
CALL Option | 1.91% | — |
#16
Prev: #—
|
4.3 | 50,000 | no change |
NEW
|
50,000 | $2,622,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SRZN
SURROZEN INC
|
Healthcare | 1.87% | 2.62% |
#17
5
Prev: #12
|
0.7 | -136,515 | -54.6% |
P
S
|
113,631 | $2,568,061 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ARE
CALL
ALEXANDRIA REAL...
|
CALL Option | 1.79% | — |
#18
Prev: #—
|
4.2 | 50,000 | no change |
NEW
|
50,000 | $2,447,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XFOR
X4 PHARMACEUTIC...
|
Healthcare | 1.73% | 2.94% |
#19
9
Prev: #10
|
0.7 | -462,765 | -43.8% |
P
S
|
593,573 | $2,374,292 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RARE
CALL
ULTRAGENYX PHAR...
|
CALL Option | 1.68% | — |
#20
Prev: #—
|
4.2 | 100,000 | no change |
NEW
|
100,000 | $2,300,000 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AYTU
AYTU BIOPHARMA ...
|
Healthcare | 1.54% | 1.36% |
#21
2
Prev: #19
|
1.1 | -78,151 | -8.8% |
P
S
|
813,704 | $2,115,630 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NKTR
CALL
NEKTAR THERAPEU...
|
CALL Option | 1.54% | — |
#22
Prev: #—
|
4.1 | 50,000 | no change |
NEW
|
50,000 | $2,114,000 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DAWN
DAY ONE BIOPHAR...
|
Healthcare | 1.36% | 3.71% |
#23
17
Prev: #6
|
0.5 | -447,382 | -69.1% |
P
S
|
200,000 | $1,864,000 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ACET
ADICET BIO INC
|
Healthcare | 1.35% | — |
#24
Prev: #—
|
4.0 | 220,011 | no change |
NEW
|
220,011 | $1,852,493 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SPRB
SPRUCE BIOSCIEN...
|
Healthcare | 1.26% | — |
#25
Prev: #—
|
4.0 | 19,742 | no change |
NEW
|
19,742 | $1,719,726 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
HRTX
HERON THERAPEUT...
|
Healthcare | 1.17% | 0.87% |
#26
2
Prev: #28
|
3.0 | 387,702 | 45.6% |
P
S
|
1,237,802 | $1,609,143 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ENTA
ENANTA PHARMACE...
|
Healthcare | 1.15% | 2.97% |
#27
18
Prev: #9
|
0.5 | -205,000 | -67.2% |
P
S
|
100,000 | $1,577,000 | 2015 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PMVP
PMV PHARMACEUTI...
|
Healthcare | 1.05% | 1.56% |
#28
11
Prev: #17
|
0.9 | -219,380 | -16.0% |
P
S
|
1,150,759 | $1,438,449 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CAMP
CAMP4 THERAPEUT...
|
Healthcare | 1.02% | — |
#29
Prev: #—
|
3.9 | 228,894 | no change |
NEW
|
228,894 | $1,403,120 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ELDN
ELEDON PHARMACE...
|
Healthcare | 0.98% | — |
#30
Prev: #—
|
3.9 | 893,100 | no change |
NEW
|
893,100 | $1,348,581 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MIST
MILESTONE PHARM...
|
Healthcare | 0.98% | — |
#31
Prev: #—
|
3.9 | 662,666 | no change |
NEW
|
662,666 | $1,338,585 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OABI
OMNIAB INC
|
Healthcare | 0.95% | 2.79% |
#32
21
Prev: #11
|
0.4 | -1,441,857 | -67.3% |
P
S
|
701,000 | $1,296,850 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
QNRX
QUOIN PHARMACEU...
|
Healthcare | 0.82% | — |
#33
Prev: #—
|
3.8 | 78,189 | no change |
NEW
|
78,189 | $1,128,267 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LUNG
PULMONX CORP
|
Healthcare | 0.78% | 0.88% |
#34
8
Prev: #26
|
0.3 | -183,600 | -27.4% |
P
S
|
486,400 | $1,074,944 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GERN
GERON CORP
|
Healthcare | 0.78% | 1.78% |
#35
19
Prev: #16
|
0.3 | -794,200 | -49.6% |
P
S
|
805,800 | $1,063,656 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABEO
CALL
ABEONA THERAPEU...
|
CALL Option | 0.77% | — |
#36
Prev: #—
|
3.8 | 200,000 | no change |
NEW
|
200,000 | $1,054,000 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
CRESCENT BIOPHA...
|
—
|
Unknown | 0.76% | — |
#37
Prev: #—
|
3.8 | 87,682 | no change |
NEW
|
87,682 | $1,039,909 | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
KZR
KEZAR LIFE SCIE...
|
Healthcare | 0.72% | 1.21% |
#38
17
Prev: #21
|
0.3 | -227,003 | -59.2% |
P
S
|
156,179 | $982,366 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EDSA
EDESA BIOTECH I...
|
Healthcare | 0.71% | 1.38% |
#39
21
Prev: #18
|
1.3 | no change | no change |
P
S
|
687,500 | $976,250 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BOLD
BOUNDLESS BIO I...
|
Healthcare | 0.62% | 0.41% |
#40
1
Prev: #41
|
3.2 | 296,618 | 71.7% |
P
S
|
710,071 | $852,085 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RADX
RADIOPHARM THER...
|
Healthcare | 0.62% | — |
#41
Prev: #—
|
3.7 | 51,000,000 | no change |
NEW
|
51,000,000 | $850,851 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SMLR
SEMLER SCIENTIF...
|
Healthcare | 0.56% | — |
#42
Prev: #—
|
3.7 | 50,000 | no change |
NEW
|
50,000 | $764,500 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MXCT
MAXCYTE INC
|
Healthcare | 0.53% | 0.59% |
#43
11
Prev: #32
|
0.7 | 10,000 | 2.2% |
P
S
|
469,018 | $726,978 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ANTX
AN2 THERAPEUTIC...
|
Healthcare | 0.52% | 0.58% |
#44
11
Prev: #33
|
2.2 | 63,755 | 11.3% |
P
S
|
627,668 | $715,542 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GOSS
GOSSAMER BIO IN...
|
Healthcare | 0.46% | 0.44% |
#45
5
Prev: #40
|
1.2 | no change | no change |
P
S
|
204,770 | $634,787 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ZNTL
ZENTALIS PHARMA...
|
Healthcare | 0.46% | 0.56% |
#46
12
Prev: #34
|
0.7 | 9,900 | 2.2% |
P
S
|
463,700 | $625,995 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BIOA
BIOAGE LABS INC
|
Healthcare | 0.43% | 0.90% |
#47
23
Prev: #24
|
0.2 | -143,571 | -76.1% |
P
S
|
45,000 | $595,350 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MNKD
MANNKIND CORP
|
Healthcare | 0.36% | 0.69% |
#48
17
Prev: #31
|
0.1 | -71,210 | -45.2% |
P
S
|
86,359 | $489,656 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CGEN
COMPUGEN LTD
|
Healthcare | 0.34% | — |
#49
Prev: #—
|
3.6 | 305,400 | no change |
NEW
|
305,400 | $467,262 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CDXS
CODEXIS INC
|
Healthcare | 0.30% | 0.18% |
#50
1
Prev: #51
|
3.1 | 167,842 | 190.2% |
P
S
|
256,106 | $417,453 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-50 of 89 holdings